Adrenocorticotropic Axis and Neuropathic Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic pain is often associated with a chronic stress and HHSG axis plays a pivotal role in maintaining homeostasis. The literature reports that pain in patients treated with opioids, significant changes are taking place in this axis with a collapse in hormone concentrations that are correlated with the decline on tests of quality of life and psychological testing. The investigators hypothesis is that this "endocrinopathy" could also be present in patients treated for neuropathic pain with other drug classes as opiates (antidepressants, antiepileptics), and may explain, at least in part, the impairement of the quality of life of these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Correlation Between 3 Phase Bone Scintigraphy and Pressure Pain Thresholds in Patients With Complex Regional Pain Syndrome (CRPS)

NCT01623141

Complex Regional Pain Syndrome Type I of the Upper Limb Unilateral Limb Pain of Other Origin Healthy Subjects

COMPLETED

Behavioral and Cognitive Predictors of Persistent Pain and Opioid Misuse in Chronic Pain

NCT06288282

Chronic Back Pain

RECRUITING

Characterization of Secondary Hyperalgesia in Healthy Volunteers

NCT02166164

Experimental Pain in Healthy Males

COMPLETED NA

PAIN Empathy Assessment in Sleep Deprived Emergency & Acute Care Clinicians

NCT05235035

Empathy Sleep Pain

COMPLETED

Neural Therapy in Notalgia Paresthetica

NCT06508073

Notalgia Paresthetica

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Day of inclusion: Blood sample for analysis of several hormones (cortisol, ACTH, SHBG, total testostérone et S-DHEA, βœstradiol et progestérone for women, LH, FSH).

Day +1: salivary samples (at wake-up, 30 minutes after wake-up, at lunch, at 06:00 pm and before sleep).

Day +2: salivary samples (at wake-up, 30 minutes after wake-up).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuropathic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Group of patients
* Patients older than 18 years,
* Male or Female with BMI between 18 and 35,
* Patients with chronic neuropathic pain for more than six months, except to diabetes or central neuropathic pain
* Patients receiving systemic therapy for treating chronic neuropathic pain such as antidepressants, anticonvulsants or opiates for at least 6 months.

Group of healthy volunteers

* non-painful healthy volunteers matched by age, sex, BMI and menopausal status for women,
* Free of analgesics within 8 days before the test,
* Aged over 18 years,
* Male or Female,

Exclusion Criteria

* Subjects with a medical history and / or surgical judged by the investigator or his representative as being incompatible with the test
* Patients treated only by topical treatment (lidocaine patch only for example)
* Pateints receiving corticosteroid treatment at the time of enrollment, or who received such treatment during the last 6 months (regardless of the dosage form and dosage),
* Inflammatory and evolutive pathology requiring long term treatment,
* Type 2 diabetes,
* Postmenopausal women with replacement therapy,
* Weight change of more than 5% within 3 months before the study,
* BMI \<18 or\> 35,

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes